Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
KROS 
Keros Therapeutics Inc (KROS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: KROS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -68.81% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 387.37M USD | Price to earnings Ratio - | 1Y Target Price 35.5 |
Price to earnings Ratio - | 1Y Target Price 35.5 | ||
Volume (30-day avg) 827882 | Beta 1.4 | 52 Weeks Range 9.41 - 72.37 | Updated Date 04/1/2025 |
52 Weeks Range 9.41 - 72.37 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1750.63% |
Management Effectiveness
Return on Assets (TTM) -26.73% | Return on Equity (TTM) -41.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -129770844 | Price to Sales(TTM) 109.12 |
Enterprise Value -129770844 | Price to Sales(TTM) 109.12 | ||
Enterprise Value to Revenue 6490.26 | Enterprise Value to EBITDA -13.05 | Shares Outstanding 40562000 | Shares Floating 35425675 |
Shares Outstanding 40562000 | Shares Floating 35425675 | ||
Percent Insiders 2.3 | Percent Institutions 104.01 |
Analyst Ratings
Rating 4.36 | Target Price 43.55 | Buy 3 | Strong Buy 8 |
Buy 3 | Strong Buy 8 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Keros Therapeutics Inc
Company Overview
History and Background
Keros Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for the treatment of hematological and pulmonary disorders with high unmet medical need. Founded in 2017, Keros has rapidly advanced its pipeline of activin receptor-like kinase (ALK) inhibitors.
Core Business Areas
- Hematology: Development of therapies for hematological disorders, including myelodysplastic syndromes (MDS) and anemia.
- Pulmonary: Development of therapies for pulmonary disorders, including pulmonary arterial hypertension (PAH).
Leadership and Structure
Keros Therapeutics is led by a management team with experience in drug development and commercialization. The company has a scientific advisory board composed of experts in hematology and pulmonary medicine.
Top Products and Market Share
Key Offerings
- KER-050: KER-050 is an investigational engineered ligand trap designed to enhance erythropoiesis and treat cytopenias in myelodysplastic syndromes (MDS) and anemia. Market share data is not yet applicable as it is in clinical development. Competitors include Bristol Myers Squibb (REBLOZYL) and Acceleron Pharma (acquired by Merck).
- KER-047: KER-047 is an investigational ALK2 inhibitor being developed for the treatment of pulmonary arterial hypertension (PAH). Market share data is not yet applicable as it is in clinical development. Competitors include Johnson & Johnson (Opsynvi, Uptravi), United Therapeutics (Remodulin, Tyvaso).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and driven by innovation. The hematology and pulmonary therapeutic areas represent significant markets with unmet needs. Increased regulatory scrutiny and approval standards present ongoing challenges.
Positioning
Keros Therapeutics is positioned as an innovative company focused on developing novel therapeutics targeting the TGF-beta superfamily. Its competitive advantage lies in its specific ALK inhibitor technology and focus on niche indications within hematology and pulmonary diseases.
Total Addressable Market (TAM)
The TAM for MDS and PAH is substantial. The market value is estimated to be in the billions of dollars, with Keros positioned to capture a portion of this market with successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel ALK inhibitor technology
- Strong intellectual property portfolio
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited commercial infrastructure
- Reliance on clinical trial success
- Dependence on financing for development
- Relatively small company size
Opportunities
- Successful clinical trial results
- Regulatory approvals for key products
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Changes in healthcare policy
Competitors and Market Share
Key Competitors
- BMY
- MRK
- JNJ
- UTHR
Competitive Landscape
Keros Therapeutics faces competition from established pharmaceutical companies with larger resources and existing market presence. Keros' advantage lies in its novel technology and focus on specific niche indications.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Keros' historical growth is reflected in its pipeline expansion and advancement of clinical programs.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of its product candidates. Analyst projections vary but generally forecast significant revenue growth if KER-050 and KER-047 are approved.
Recent Initiatives: Recent initiatives include advancing KER-050 and KER-047 through clinical trials, expanding the pipeline with new preclinical programs, and securing partnerships with strategic investors.
Summary
Keros Therapeutics is a clinical-stage biopharmaceutical company with a promising pipeline targeting unmet needs in hematology and pulmonary diseases. Its novel ALK inhibitor technology offers a competitive advantage. Success hinges on clinical trial results and regulatory approvals, making it a high-risk, high-reward investment. Dependence on financing and competition from larger firms are key challenges.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
MRK
Merck & Company Inc
MRK
Merck & Company Inc
UTHR
United Therapeutics Corporation
UTHR
United Therapeutics Corporation
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Keros Therapeutics Inc. Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in biotechnology companies involves significant risks, including clinical trial failures and regulatory setbacks. Consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Keros Therapeutics Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2020-04-08 | CEO & Chair of the Board Dr. Jasbir S. Seehra Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 169 | Website https://www.kerostx.com |
Full time employees 169 | Website https://www.kerostx.com | ||
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.